Replimune’s fight with the FDA deepens
The oncolytic virus vuso-vec is slapped with its second CRL.
Bicycle finally falls
The company admits defeat with zelenectide.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
